The global epinephrine market size was estimated to be USD 1.95 billion in 2023 and is expected to reach at USD 6.41 billion by 2034 with a CAGR of 11.42% during the forecast period 2024-2034. Rising prevalence of anaphylaxis & asthma, surge in favourable reimbursement policies for epinephrine auto injectors, growing launches of technologically advanced products, increasing prevalence of various diseases including anaphylaxis, cardiovascular diseases, & others, rising awareness regarding the treatment options for the management of these diseases, surge in advancements in auto-injectors such as Al-enabled auto- injectors & needle-free auto-injectors, many major players in the industry are adopting growth strategies including engaging in acquisitions & collaborations to advance the development of technologically sophisticated injectors are some of the key factors boosting the market growth.
Many major players in the industry are adopting growth strategies including engaging in acquisitions & collaborations to advance the development of technologically sophisticated injectors is predicted to boost the market growth during the forecast period. Anaphylaxis is an intense allergic reaction that can result from exposure to specific foods, insect stings, medications, and allergy immunotherapy injection devices. The main therapy for anaphylaxis and incidents of asthma is epinephrine. This medication can be administered through different methods, including intramuscular, subcutaneous, intravenous, and inhalation. Hence, market players are focusing on the development of novel products. For instance, in July 2022, Neffy is an epinephrine nasal spray, and ARS Pharmaceuticals and Silverback Therapeutics have partnered to work together on its regulatory approval and marketing.
By product, auto-injectors was the highest revenue-grossing segment in the global epinephrine market in 2023 owing to the advantages of these auto-injectors over alternative products include easy usability, convenient handling, & various other benefits and growing demand for the emergency treatment of acute anaphylaxis due to their ability to facilitate fast absorption of the drug. Additionally, pre-filled syringes is predicted to grow at fastest CAGR during the forecast period owing to the rapid response to emergency allergic reactions, growing demand for the treatment of various illnesses by hospitals & clinics, and increasing regulatory approvals. For instance, in August 2022, Amphastar Pharmaceuticals Inc. has reported that the U.S. Food and Drug Administration (FDA) approved the company's New Drug Application for the Epinephrine Single Dose Pre-Filled Syringe.
By application, anaphylaxis was the highest revenue-grossing segment in the global epinephrine market in 2023 owing to the increase in the prevalence of anaphylaxis, accompanied by the introduction of new & innovative products. For instance, in March 2023, Daiichi Sankyo, Inc., via its subsidiary American Regent, Inc., has introduced sulfite-free Epinephrine Injection, USP. This medication is intended exclusively for the treatment of type I allergic responses in an emergency. Additionally, respiratory disorders is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness of available treatment options for respiratory disorders and the rising rates of diagnosis & treatment for respiratory conditions.
By distribution channel, retail & online pharmacy was the highest revenue-grossing segment in the global epinephrine market in 2023 owing to the expanding presence of both retail and online pharmacy stores, coupled with the widespread availability of auto-injectors and their easy accessibility on companies' online platforms, enhances the convenience of procuring these products. Additionally, hospital pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the rising frequency of emergency hospital visits by patients is attributed to severe allergic reactions, cardiac arrest, & respiratory conditions and growing collaborations within market players. For instance, in August 2022, A ten-year commercialization agreement has been signed by Kaleo, Inc. and Valeo Pharma for the sales of ALLERJECT in Canada.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing reimbursement policies for auto-injectors, growing launch of technologically advanced products, surge in prevalence of anaphylaxis, cardiovascular diseases, & others, and rising approvals by regulatory authorities. For instance, in August 2022, The FDA has approved Sanofi's Auvi-Q, the company's first voice-guided adrenaline auto-injector intended for use in patients with severe allergies. The approval grants Sanofi a license to commercialize Auvi-Q from Intelliject Inc. in North America, while the company retains commercialization rights for the rest of the world. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the diagnosis & treatment rates of anaphylaxis are on the rise, companies are expanding globally in response to the growing demand for auto-injectors, while regulations pertaining to their use are changing, growing launch of new products, and rising mergers & acquisitions within market players. For instance, in February 2022, Sanofi has obtained Amunix, providing access to Amunix's Pro-XTEN, XPAT, and XPAC technology for the development of advanced Conditionally Activated Biologics.
Many major players in the industry are adopting growth strategies including engaging in acquisitions & collaborations to advance the development of technologically sophisticated injectors is predicted to boost the market growth during the forecast period. Anaphylaxis is an intense allergic reaction that can result from exposure to specific foods, insect stings, medications, and allergy immunotherapy injection devices. The main therapy for anaphylaxis and incidents of asthma is epinephrine. This medication can be administered through different methods, including intramuscular, subcutaneous, intravenous, and inhalation. Hence, market players are focusing on the development of novel products. For instance, in July 2022, Neffy is an epinephrine nasal spray, and ARS Pharmaceuticals and Silverback Therapeutics have partnered to work together on its regulatory approval and marketing.
By product, auto-injectors was the highest revenue-grossing segment in the global epinephrine market in 2023 owing to the advantages of these auto-injectors over alternative products include easy usability, convenient handling, & various other benefits and growing demand for the emergency treatment of acute anaphylaxis due to their ability to facilitate fast absorption of the drug. Additionally, pre-filled syringes is predicted to grow at fastest CAGR during the forecast period owing to the rapid response to emergency allergic reactions, growing demand for the treatment of various illnesses by hospitals & clinics, and increasing regulatory approvals. For instance, in August 2022, Amphastar Pharmaceuticals Inc. has reported that the U.S. Food and Drug Administration (FDA) approved the company's New Drug Application for the Epinephrine Single Dose Pre-Filled Syringe.
By application, anaphylaxis was the highest revenue-grossing segment in the global epinephrine market in 2023 owing to the increase in the prevalence of anaphylaxis, accompanied by the introduction of new & innovative products. For instance, in March 2023, Daiichi Sankyo, Inc., via its subsidiary American Regent, Inc., has introduced sulfite-free Epinephrine Injection, USP. This medication is intended exclusively for the treatment of type I allergic responses in an emergency. Additionally, respiratory disorders is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness of available treatment options for respiratory disorders and the rising rates of diagnosis & treatment for respiratory conditions.
By distribution channel, retail & online pharmacy was the highest revenue-grossing segment in the global epinephrine market in 2023 owing to the expanding presence of both retail and online pharmacy stores, coupled with the widespread availability of auto-injectors and their easy accessibility on companies' online platforms, enhances the convenience of procuring these products. Additionally, hospital pharmacy is predicted to grow at fastest CAGR during the forecast period owing to the rising frequency of emergency hospital visits by patients is attributed to severe allergic reactions, cardiac arrest, & respiratory conditions and growing collaborations within market players. For instance, in August 2022, A ten-year commercialization agreement has been signed by Kaleo, Inc. and Valeo Pharma for the sales of ALLERJECT in Canada.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing reimbursement policies for auto-injectors, growing launch of technologically advanced products, surge in prevalence of anaphylaxis, cardiovascular diseases, & others, and rising approvals by regulatory authorities. For instance, in August 2022, The FDA has approved Sanofi's Auvi-Q, the company's first voice-guided adrenaline auto-injector intended for use in patients with severe allergies. The approval grants Sanofi a license to commercialize Auvi-Q from Intelliject Inc. in North America, while the company retains commercialization rights for the rest of the world. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the diagnosis & treatment rates of anaphylaxis are on the rise, companies are expanding globally in response to the growing demand for auto-injectors, while regulations pertaining to their use are changing, growing launch of new products, and rising mergers & acquisitions within market players. For instance, in February 2022, Sanofi has obtained Amunix, providing access to Amunix's Pro-XTEN, XPAT, and XPAC technology for the development of advanced Conditionally Activated Biologics.
Segmentation: Epinephrine Market Report 2023 - 2034
Epinephrine Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Pre-Filled Syringes
- Auto-Injectors
- Ampoules & Vials
Epinephrine Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Respiratory Disorders
- Anaphylaxis
- Cardiac Arrest
- Others
Epinephrine Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacy
- Retail & Online Pharmacy
Epinephrine Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Epinephrine Market: Product Estimates & Trend Analysis
8. Epinephrine Market: Application Estimates & Trend Analysis
9. Epinephrine Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Epinephrine Market
12. Europe Global Epinephrine Market
13. Asia Pacific Global Epinephrine Market
14. Latin America Global Epinephrine Market
15. MEA Global Epinephrine Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Kaleo Inc.
- USWM LLC.
- Viatris Inc.
- Amneal Pharmaceuticals LLC.
- ALK-Abelló A/S
- BIOPROJET
- Teva Pharmaceutical Industries Ltd.
- Bausch Health Companies Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.95 Billion |
| Forecasted Market Value ( USD | $ 6.41 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
